Business
Blue Water Biotech to Present Corporate Overview and ENTADFI® Launch Plan at the JMP Securities Life Sciences Conference in New York, NY
CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational
About this update from Onconetix, Inc.
[{"type":"text","content":"CINCINNATI, May 10, 2023 (GLOBE NEWSWIRE) -- Blue Water Biotech, Inc. (“Blue Water” or the “Company”), a biopharmaceutical company developing transformational therapies to address significant global health challenges, today announced that Blue Water management will present at the JMP Securities Life Sciences Conference at the New York Hilton Midtown on Monday, May 15th at 3:30pm EDT. Session details are as follows: Date:Monday, May 15th, 2023Time:3:30pm EDTLocation:New York Hilton Midtown, Room ETitle:Blue Water Biotech Overview and ENTADFI® Launch Plan At the conference, Blue Water management will present a corporate overview and highlight its launch plan for ENTADFI®, an FDA-approved treatment for benign prostatic hyperplasia (“BPH”) that counteracts negative sexual side effects seen in men on alternative BPH therapies. “Following our purchase of ENTADFI® in April, we are excited to share our launch strategy with the investment community,” said Joseph Hernandez, Chairman and Chief Executive Officer of Blue Water. “We believe ENTADFI® has the potential to transform the BPH space and positively impact the lives of millions of men, and we look forward to sharing our strategy with all in attendance.” Blue Water management will be available during the conference for one-on-one meetings. Interested parties may request a one-on-one meeting at [email protected] or contact Blue Water at (513) 620-4101. About ENTADFI® ENTADFI® is an oral, once daily treatment for BPH that combines finasteride, a 5α-reductase inhibitor, and tadalafil, a phosphodiesterase 5 (PDE5) inhibitor, offering a more effective treatment option compared to other available therapies. Clinical trials have shown that ENTADFI® is more effective in treating BPH symptoms, including urinary frequency, urgency, weak stream, and difficulty initiating or maintaining urination, compared to finasteride monotherapy. Additionally, ENTADFI® has demonstrated a favorable safety profile, with fewer adverse sexual side effects compared to finasteride. ENTADFI® reduces potential for adverse sexual side effects, making it a preferred choice for men seeking relief from BPH symptoms without compromising their sexual health. ENTADFI® has received FDA approval for the indication of initiating treatment of the signs and symptoms of BPH in men with an enlarged prostate for up to 26 weeks...